Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FANCF$0.42-0.02(-3.99%)First Atlantic to Acquire 100% of the North Arm Project, 52 sq km of Mantle-Derived Ultramafic Rocks in Western Newfoundland Never Systematically Tested for Geologic Hydrogen, Chromium or Awaruite Nickel-Cobalt Alloy[8:30:00 PM ET]NEXNF$0.09-0.00(-2.45%)NEXE Innovations Reports Q1 Fiscal 2027 Results and Business Update[8:03:56 PM ET]UREKF$0.120.00(0.00%)Eureka Metals Corp. Announces Rights Offering and Proposed Share Consolidation[7:57:00 PM ET]RMBI$15.860.00(0.00%)RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES 2026 THIRD QUARTER FINANCIAL RESULTS Richmond Mutual Bancorporation, Inc., a Maryland corporation (the "Company") (NASDAQ: RMBI), parent company of First Bank Midwest, today reported net ...[7:55:00 PM ET]MVLY$21.69+0.73(+3.48%)Mission Valley Bancorp Reports Third Quarter Results[7:52:00 PM ET]UNIB$21.350.00(0.00%)University Bancorp Closes on the Acquisition of 20% of UIF Corporation for Cash & Stock Worth About $15.2 Million[7:45:00 PM ET]NXTT$5.02+0.17(+3.51%)Next Technology Holding Inc. Announces Board Authorization to Sell or Pledge of Bitcoin Holdings to Reduce Bitcoin Exposure and Enhance Liquidity[7:20:00 PM ET]PRRSF$0.04+0.00(+10.13%)Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement[6:35:00 PM ET]OTAI$10.11+0.00(+0.05%)Spider Digital Technology Ltd. and Starlink AI Acquisition Corporation Announce Definitive Business Combination Agreement[6:30:00 PM ET]REVVF$0.170.00(0.00%)Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario[6:30:00 PM ET]CTSH$64.90+2.38(+3.81%)Cognizant setzt mehr als 25.000 Fachkräfte für die Umsetzung von OpenAI-Lösungen ein, während Unternehmen bahnbrechende KI-Technologien in die Produktion überführen Cognizant (Nasdaq: CTSH) gab heute die Gründung seiner „OpenAI Frontier Capability Group" bekannt, in der mehr als 25.000 Fachkräfte zusammenkommen,...[6:17:00 PM ET]INO$2.06+1.29(+166.91%)INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...[6:01:00 PM ET]

INSM · NASDAQ

Insmed Incorporated

$112.01 +14.71 (+15.17%)

Company overview

Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$24.5B
Employees
1,271
Headquarters
Bridgewater, NJ
Website
insmed.com
CEO
William H. Lewis
Listed
June 1, 2000
P/E
-19.48
Dividend yield
0.00%

Company financials

Revenue
$820M
Gross profit
$668M
Operating income
-$1.1B
EBITDA
-$1.1B
Net income
-$1.2B
EPS
-$5.75
Total assets
$2.1B
Total debt
$748M
Gross margin
81.56%
Net margin
-144.44%
Earnings yield
-5.13%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

88.29102.47116.65130.82145.00
INSM 1D NASDAQ O107.40H114.51L106.75C111.69+14.71 (+15.17%)Vol2.56M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
INSMInsmed Incorporated Stock news INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance Zacks Investment Research
INSMInsmed Incorporated Stock news What Insmed (INSM) Said on Its Q3 Earnings Call MarketBeat
INSMInsmed Incorporated Stock news Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research
INSMInsmed Incorporated Stock news Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates Zacks Investment Research
INSMInsmed Incorporated Press release Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to... PR Newswire
INSMInsmed Incorporated Stock news Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks Investment Research
INSMInsmed Incorporated Press release Insmed Appoints Two New Directors to Its Board Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to... PR Newswire
INSMInsmed Incorporated Press release Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- a. PR Newswire
INSMInsmed Incorporated Press release Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to del. PR Newswire
INSMInsmed Incorporated Press release Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to... PR Newswire
INSMInsmed Incorporated Stock news This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Benzinga
INSMInsmed Incorporated Stock news INSM Stock Slides on CFO Exit, Reiterates '26 Sales View Zacks Investment Research
INSMInsmed Incorporated Stock news Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed Benzinga
INSMInsmed Incorporated Press release Insmed Announces CFO Transition PRNewsWire
INSMInsmed Incorporated Stock news 3 Healthcare Stocks Showing Why the Sector Still Has Momentum MarketBeat
INSMInsmed Incorporated Stock news FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce Zacks Investment Research
INSMInsmed Incorporated Stock news Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case Seeking Alpha
INSMInsmed Incorporated Press release FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 PR Newswire
INSMInsmed Incorporated Press release Insmed Expands Community Impact During Fifth Annual Global Day of Good PR Newswire
INSMInsmed Incorporated Stock news Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
See more
FAQ

Questions about Insmed Incorporated

What does Insmed Incorporated do?
Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
What is INSM's market cap?
Insmed Incorporated (INSM) is a listed stock with a live quote. The latest market cap on this page is $24.5B.
Where is Insmed Incorporated headquartered?
Insmed Incorporated is headquartered in Bridgewater, NJ.
How do I get INSM news from the API?
Call GET /v1/news?tickers=INSM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does INSM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for INSM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the INSM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs